Patents by Inventor Justin J. Taylor

Justin J. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150444
    Abstract: Antibodies that protect against respiratory viral infections including human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are described. Certain antibodies disclosed herein neutralize more than one virus (e.g., RSV and HMPV). The binding fragments of the antibodies can be engineered into numerous formats including those that provide simultaneous protection against multiple viruses.
    Type: Application
    Filed: February 25, 2022
    Publication date: May 9, 2024
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Jim Boonyaratanakornkit
  • Publication number: 20240131132
    Abstract: Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses.
    Type: Application
    Filed: October 22, 2023
    Publication date: April 25, 2024
    Applicants: Fred Hutchinson Cancer Center, University of Washington
    Inventors: Justin J. Taylor, Denise Galloway, Paul Nghiem, David Koelle, Haroldo Rodriguez, Joseph Carter
  • Publication number: 20240052013
    Abstract: Systems and methods to link CD40 signaling to antigen binding, independently of CD40 ligand binding are described. The systems and methods include fusion proteins including an extracellular antigen binding domain linked to an intracellular CD40 signaling domain.
    Type: Application
    Filed: February 8, 2022
    Publication date: February 15, 2024
    Applicants: Fred Hutchinson Cancer Center, University of Washington
    Inventors: Justin J. Taylor, Laila Shehata, Marti Tooley
  • Publication number: 20230331850
    Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.
    Type: Application
    Filed: January 23, 2023
    Publication date: October 19, 2023
    Inventors: Brian T, Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor
  • Publication number: 20230250159
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: February 8, 2023
    Publication date: August 10, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Patent number: 11578118
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: February 14, 2023
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Patent number: 11560432
    Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: January 24, 2023
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Brian T. Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor
  • Publication number: 20210198344
    Abstract: Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and/or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Justin J. Taylor, Howell F. Moffett
  • Publication number: 20180298103
    Abstract: Phycoerythrin (PE) and peptide:MHCII (p:MHCII) reactive monoclonal antibodies; methods to generate monoclonal antibodies including, for example, peptide:MHC (p:MHC) reactive monoclonal antibodies; compositions including monoclonal antibodies; and uses thereof.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Brian T. Fife, Justin A. Spanier, Marc K. Jenkins, Justin J. Taylor